Nutriband Inc. Quarterly Report Highlights Record Revenue for Q2, 2025 up 50.87% YOY and Strategic Progress Toward NDA Filing for AVERSA Fentanyl
Nutriband (NASDAQ:NTRB) reported strong Q2 2025 financial results, with revenue reaching $1,289,884, marking a 50.87% increase year-over-year. The company maintains a robust cash position of $6.9 million, with total assets of $10.17 million and stockholders' equity of $8.5 million.
The company is advancing its lead product, AVERSA Fentanyl, with a scheduled Type C meeting on September 18th. Notably, the NDA filing will require only a single phase 1 Human Abuse Potential study, without the need for Phase 2 or 3 trials. Market analysis projects potential peak annual sales of $80-$200 million for AVERSA Fentanyl and up to $130 million for AVERSA Buprenorphine.
Nutriband (NASDAQ:NTRB) ha registrato risultati finanziari solidi nel secondo trimestre 2025, con ricavi pari a $1.289.884, in aumento del 50,87% rispetto all'anno precedente. La società dispone di una posizione di cassa solida di $6,9 milioni, attività totali per $10,17 milioni e patrimonio netto di $8,5 milioni.
L'azienda sta portando avanti il suo prodotto principale, AVERSA Fentanyl, e ha programmato un incontro di tipo C per il 18 settembre. È importante sottolineare che la presentazione della NDA richiederà solo uno studio di fase 1 sulla potenziale abusività umana, senza necessità di studi di fase 2 o 3. Le analisi di mercato stimano vendite annue di picco potenziali tra $80 e $200 milioni per AVERSA Fentanyl e fino a $130 milioni per AVERSA Buprenorphine.
Nutriband (NASDAQ:NTRB) presentó sólidos resultados financieros en el segundo trimestre de 2025, con ingresos por $1,289,884, lo que supone un aumento interanual del 50,87%. La compañía mantiene una posición de caja sólida de $6.9 millones, activos totales por $10.17 millones y patrimonio de los accionistas de $8.5 millones.
La empresa está avanzando con su producto principal, AVERSA Fentanyl, y tiene programada una reunión Tipo C el 18 de septiembre. Cabe destacar que la presentación de la NDA requerirá solo un estudio de fase 1 sobre el potencial de abuso humano, sin necesidad de ensayos de fase 2 o 3. Los análisis de mercado proyectan ventas anuales máximas potenciales de $80-$200 millones para AVERSA Fentanyl y hasta $130 millones para AVERSA Buprenorphine.
Nutriband (NASDAQ:NTRB)는 2025년 2분기 강력한 실적을 발표했으며, 매출은 $1,289,884로 전년 대비 50.87% 증가했습니다. 회사는 $6.9백만의 견실한 현금 보유고를 유지하고 있으며, 총자산은 $10.17백만, 자기자본은 $8.5백만입니다.
회사는 주력 제품인 AVERSA Fentanyl을 개발 중이며 9월 18일 Type C 미팅이 예정되어 있습니다. 주목할 점은 NDA 제출을 위해 인체 남용 가능성(Human Abuse Potential) 관련 단 한 건의 1상 시험만 필요하며 2상이나 3상 시험은 요구되지 않는다는 것입니다. 시장 분석은 AVERSA Fentanyl의 연간 최대 잠재 매출을 $80~$200백만, AVERSA Buprenorphine은 최대 $130백만으로 추정합니다.
Nutriband (NASDAQ:NTRB) a publié de solides résultats financiers pour le deuxième trimestre 2025 : un chiffre d'affaires de $1,289,884, soit une hausse de 50,87% d'une année sur l'autre. La société dispose d'une trésorerie solide de $6,9 millions, d'actifs totaux de $10,17 millions et de capitaux propres de $8,5 millions.
L'entreprise fait progresser son produit phare, AVERSA Fentanyl, et a prévu une réunion de type C le 18 septembre. Il est notable que le dépôt de la NDA nécessitera seulement une étude de phase 1 sur le potentiel d'abus humain, sans besoin d'essais de phase 2 ou 3. Les analyses de marché estiment des ventes annuelles maximales potentielles de $80-$200 millions pour AVERSA Fentanyl et jusqu'à $130 millions pour AVERSA Buprenorphine.
Nutriband (NASDAQ:NTRB) meldete starke Finanzergebnisse für das zweite Quartal 2025: Der Umsatz belief sich auf $1.289.884, ein Anstieg von 50,87% im Jahresvergleich. Das Unternehmen verfügt über eine solide Barreserve von $6,9 Millionen, Gesamtvermögen von $10,17 Millionen und Eigenkapital von $8,5 Millionen.
Das Unternehmen treibt sein Hauptprodukt, AVERSA Fentanyl, voran und hat ein Type-C-Meeting für den 18. September angesetzt. Auffällig ist, dass die NDA-Einreichung lediglich eine Phase-1-Studie zur Human Abuse Potential erfordert; Phase-2- oder -3-Studien sind nicht notwendig. Marktanalysen prognostizieren mögliche Höchstjahresumsätze von $80–$200 Millionen für AVERSA Fentanyl und bis zu $130 Millionen für AVERSA Buprenorphine.
- Record revenue growth of 50.87% YOY to $1,289,884
- Strong cash position of $6.9 million to support development efforts
- Simplified regulatory pathway requiring only Phase 1 study for NDA filing
- Potential peak annual sales of $80-$200 million for AVERSA Fentanyl
- Additional revenue potential of up to $130 million from AVERSA Buprenorphine
- None.
ORLANDO, Fla., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) reported its financial results for the six months ended July 31, 2025. The company reported a strong cash position at quarter end, reinforcing its ability to advance the development of its lead product, AVERSA™ Fentanyl which has been granted a Type C meeting on September 18th.
Nutriband is continuing to expand its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary. The company produced a record six months, reporting revenue of
Progress continues on the development of AVERSA Fentanyl, Nutriband is reminding exiting shareholders and updating new shareholders on its development pathway, emphasizing that the NDA will primarily rely on data from a single phase 1 Human Abuse Potential study. Importantly, no Phase 2 or Phase 3 clinical trials will be required before submission.
If approved, AVERSA Fentanyl could become the first and only abuse-deterrent transdermal patch available globally. AVERSA Fentanyl is estimated to have the potential to reach peak annual sales of
AVERSA Buprenorphine, which is the company’s second application for AVERSA, is projected to reach peak annual sales of up to
As of July 31, 2025, Nutriband’s cash reserves stand at
About Nutriband Inc.
We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.
The Company’s website is www.nutriband.com. Any material contained in or derived from Company’s websites or any other website if not part of this press release.
Forward-Looking Statements
Certain statements contained in this press release, including, without limitation, statements containing the words ‘’believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Form S-1, Form 10-K for the year ended January, 2025, filed April 28, 2025, the Forms 10-Q’s filed subsequent to the Form 10-K in 2025, and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.
For more information, contact:
Nutriband Inc.
Phone: 407-377-6695
Email: info@nutriband.com
FAQ
What was Nutriband's (NTRB) revenue growth in Q2 2025?
What is the market potential for Nutriband's AVERSA Fentanyl?
What clinical trials are required for AVERSA Fentanyl's NDA filing?
How much cash does Nutriband (NTRB) have as of July 31, 2025?
What is AVERSA Buprenorphine's projected market potential?
